RLMD vs. WBD

Last updated Apr 1, 2026

Compare and contrast key facts about Relmada Therapeutics, Inc. (RLMD) and Warner Bros. Discovery, Inc. (WBD).

Performance

RLMD vs. WBD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Relmada Therapeutics, Inc. (RLMD) and Warner Bros. Discovery, Inc. (WBD). The values are adjusted to include any dividend payments, if applicable.

RLMD vs. WBD - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
RLMD Relmada Therapeutics, Inc.	44.10%	828.85%	-87.44%	18.62%	-84.51%	-29.75%	-17.77%	747.83%	53.33%	-31.19%
WBD Warner Bros. Discovery, Inc.	-4.72%	172.66%	-7.12%	20.04%	-59.73%	-21.77%	-8.09%	32.34%	10.55%	-18.35%

Fundamentals

EPS RLMD : -$1.69 WBD : $1.01
Total Revenue (TTM) RLMD : $0.00 WBD : $37.30B
Gross Profit (TTM) RLMD : $0.00 WBD : $16.41B
EBITDA (TTM) RLMD : -$38.53M WBD : $15.03B

Returns By Period

In the year-to-date period, RLMD achieves a 44.10% return, which is significantly higher than WBD's -4.72% return. Over the past 10 years, RLMD has outperformed WBD with an annualized return of 0.23%, while WBD has yielded a comparatively lower -0.51% annualized return.

RLMD

• 1D: 9.09%
• 1M: 52.63%
• YTD: 44.10%
• 6M: 246.27%
• 1Y: 2,477.78%
• 3Y*: 45.49%
• 5Y*: -28.27%
• 10Y*: 0.23%

WBD

• 1D: 1.37%
• 1M: -2.52%
• YTD: -4.72%
• 6M: 40.60%
• 1Y: 155.92%
• 3Y*: 22.06%
• 5Y*: -8.71%
• 10Y*: -0.51%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RLMD vs. WBD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RLMD

RLMD Risk / Return Rank: 99
RLMD Sharpe Ratio Rank: 100
RLMD Sortino Ratio Rank: 99
RLMD Omega Ratio Rank: 98
RLMD Calmar Ratio Rank: 100
RLMD Martin Ratio Rank: 100

WBD

WBD Risk / Return Rank: 96
WBD Sharpe Ratio Rank: 96
WBD Sortino Ratio Rank: 95
WBD Omega Ratio Rank: 96
WBD Calmar Ratio Rank: 95
WBD Martin Ratio Rank: 95

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RLMD vs. WBD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Relmada Therapeutics, Inc. (RLMD) and Warner Bros. Discovery, Inc. (WBD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RLMD	WBD	Difference
Sharpe ratio Return per unit of total volatility	15.47	2.70	+12.77
Sortino ratio Return per unit of downside risk	6.05	3.56	+2.50
Omega ratio Gain probability vs. loss probability	1.81	1.54	+0.27
Calmar ratio Return relative to maximum drawdown	36.54	5.82	+30.72
Martin ratio Return relative to average drawdown	113.45	16.50	+96.96
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RLMD vs. WBD - Sharpe Ratio Comparison

The current RLMD Sharpe Ratio is 15.47, which is higher than the WBD Sharpe Ratio of 2.70. The chart below compares the historical Sharpe Ratios of RLMD and WBD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RLMD	WBD	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	15.47	2.70	+12.77
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.24	-0.16	-0.08
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.00	-0.01	+0.01
Sharpe Ratio (All Time) Calculated using the full available price history	-0.15	0.08	-0.23

Correlation

The correlation between RLMD and WBD is 0.08, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

RLMD vs. WBD - Dividend Comparison

Neither RLMD nor WBD has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

RLMD vs. WBD - Drawdown Comparison

The maximum RLMD drawdown since its inception was -99.66%, which is greater than WBD's maximum drawdown of -92.58%. Use the drawdown chart below to compare losses from any high point for RLMD and WBD.

Drawdown Indicators

	RLMD	WBD	Difference
Max Drawdown Largest peak-to-trough decline	-99.66%	-92.58%	-7.08%
Max Drawdown (1Y) Largest decline over 1 year	-61.47%	-27.18%	-34.29%
Max Drawdown (5Y) Largest decline over 5 years	-99.36%	-84.54%	-14.82%
Max Drawdown (10Y) Largest decline over 10 years	-99.50%	-91.32%	-8.18%
Current Drawdown Current decline from peak	-90.65%	-69.64%	-21.01%
Average Drawdown Average peak-to-trough decline	-79.54%	-46.34%	-33.20%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.79%	9.99%	+9.80%

Volatility

RLMD vs. WBD - Volatility Comparison

Relmada Therapeutics, Inc. (RLMD) has a higher volatility of 52.68% compared to Warner Bros. Discovery, Inc. (WBD) at 3.56%. This indicates that RLMD's price experiences larger fluctuations and is considered to be riskier than WBD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RLMD	WBD	Difference
Volatility (1M) Calculated over the trailing 1-month period	52.68%	3.56%	+49.12%
Volatility (6M) Calculated over the trailing 6-month period	82.69%	22.10%	+60.59%
Volatility (1Y) Calculated over the trailing 1-year period	162.64%	58.17%	+104.47%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	116.02%	53.32%	+62.70%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	115.00%	47.31%	+67.69%

Financials